AflacAFL
AFL logo
Fair Value
US$117.71
Share price25 Jul
US$125.66.7% overvalued intrinsic discount
Loading
1Y21.51%
7D0.71%

AFL: Earnings Stability And Strong Buybacks Will Support Balanced Outlook

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published
06 Aug 24
Updated
25 Jul 26
Views
450
Not Invested

Last Update 25 Jul 26

Fair value Increased 2.49%

AFL: Future Returns Will Reflect Supportive Macro Conditions And Execution Risk Balancing

Aflac's fair value estimate has been raised from about $114.86 to $117.71 as analysts incorporate higher sector price targets, modestly higher assumed future P/E multiples, and a slightly stronger profit margin outlook supported by a more supportive macro backdrop and reduced private credit concerns across life insurers.

Analyst Commentary

Recent Street research on Aflac reflects a wide range of views on valuation and execution, even as most firms have adjusted their price targets upward in the run up to Q2 earnings.

Bullish Takeaways

  • Bullish analysts highlight that sector valuations have moved higher alongside recent stock price performance, which feeds into modestly higher assumed P/E multiples for Aflac.
  • Several firms point to a more supportive macro backdrop and fading private credit concerns across life insurers, which they view as helpful for Aflac's earnings quality and balance sheet risk profile.
  • Upward revisions to longer term operating earnings and free cash flow estimates are cited by some as a key reason for higher Aflac price targets, tying expected fundamentals to valuation assumptions.
  • Commentary around generally strong Q1 results for life insurance companies and ongoing business momentum, particularly in international operations, is used by some analysts to support constructive views on Aflac's execution.

Bearish Takeaways

  • Bearish analysts maintain more cautious ratings, including Underperform and Underweight, even when adjusting Aflac price targets. This signals concern that current valuation already reflects much of the positive thesis.
  • Mixed stock performance across U.S. life insurers earlier in the year is cited as a reason for restraint, with some analysts preferring annuity writers more broadly and keeping a Hold stance on Aflac.
  • One firm has modestly trimmed its target on Aflac, which suggests that not all observers see upside from current levels and that there is some skepticism around how much the company can expand its valuation multiple.
  • Where targets are lifted but ratings stay Neutral, analysts are effectively signaling that while sector conditions and estimates have improved, they see limited mispricing in Aflac relative to peers.

What’s in the News for Aflac

  • Aflac opened a fully staffed office in South Portland, Maine, to provide claims administration services for more than 500,000 eligible workers and participating public and private sector employers under the Maine Paid Family and Medical Leave program, which is scheduled to begin issuing benefits as of May 1. (Source: Key Developments)
  • From January 1, 2026 to March 31, 2026, Aflac repurchased 9,024,683 shares, representing 1.74% of its stock, for US$1,000m. (Source: Key Developments)
  • Since the buyback program announced on August 8, 2017, Aflac has completed the repurchase of 274,701,431 shares, representing 43.25% of its stock, for a total of US$18,667.72m under that authorization. (Source: Key Developments)

Valuation Changes for Aflac

  • Fair Value: The fair value estimate for Aflac has risen slightly from $114.86 to $117.71, reflecting a modest uplift in the underlying assumptions.
  • Discount Rate: The discount rate assumption is effectively unchanged at 7.11%, indicating a stable required return in the updated model.
  • Revenue Growth: The long term revenue growth assumption has been adjusted lower, from a decline of about 0.78% to a decline of about 1.08%.
  • Net Profit Margin: The assumed net profit margin has edged up from roughly 20.44% to 20.49%, suggesting a slightly stronger profitability outlook.
  • Future P/E: The future P/E multiple used in the valuation has risen from about 17.10x to 17.64x, which contributes to the higher $117.71 fair value for Aflac.
0 viewsusers have viewed this narrative update

Key Takeaways

  • Product innovation and digitalization expand Aflac's market reach, support topline growth, and improve operational efficiency and customer engagement.
  • Investment portfolio diversification and new distribution strategies enhance earnings stability and drive sustained long-term income growth.
  • Heavy reliance on Japan and challenging investment returns, along with weak U.S. sales growth, pose ongoing risks to Aflac's revenue, earnings, and margin stability.

Catalysts

About Aflac
    Through its subsidiaries, provides supplemental health and life insurance products.
What are the underlying business or industry changes driving this perspective?
  • The successful launch of new, customizable cancer insurance (Miraito) in Japan, coupled with strong early sales across all distribution channels-including banks and Japan Post-positions Aflac to capture growing demand for supplemental health coverage among aging and younger consumers, supporting topline revenue and premium growth.
  • Increased adoption of digital underwriting, customer-facing Gen AI, and digital human avatar initiatives in both Japan and the U.S. is expected to lower long-term operational costs and improve customer engagement, with the potential to materially expand net margins through enhanced efficiency and better scalability.
  • Heightened consumer awareness of financial health risks and rising medical costs-combined with product innovation (such as modular coverage, new children's cancer policies, and expanded group dental/vision)-broadens Aflac's addressable market and increases cross-sell opportunities, supporting both revenue and persistency.
  • Ongoing diversification and optimization of Aflac's investment portfolio, including the proactive management of yen
  • and USD-denominated assets, positions the company to better withstand interest rate cycles and enhance investment income stability, reducing earnings volatility and supporting sustainable bottom-line growth.
  • Strategic expansion in digital direct-to-consumer channels in the U.S., aggressive agent recruitment in Japan, and new partnerships with large institutions (like state-run disability leave programs) enable Aflac to extend market reach and drive sustained earned premium and fee-based income growth over the long term.
Aflac Earnings and Revenue Growth

Aflac Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

  • Analysts are assuming Aflac's revenue will decrease by 1.1% annually over the next 3 years.
  • Analysts assume that profit margins will shrink from 25.6% today to 20.5% in 3 years time.
  • Analysts expect earnings to reach $3.6 billion (and earnings per share of $7.93) by about July 2029, down from $4.6 billion today.
  • In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 17.7x on those 2029 earnings, up from 13.8x today. This future PE is greater than the current PE for the US Insurance industry at 12.2x.
  • Analysts expect the number of shares outstanding to decline by 4.83% per year for the next 3 years.
  • To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?
  •  Net earned premiums in Japan, Aflac's largest and most profitable market, continued to decline year-over-year (down 1.1% excluding one-off effects), and management's guidance recognizes ongoing negative premium growth of -1% to -2% for the foreseeable future, which could constrain future revenue and earnings growth.
  •  The company is experiencing increased technology and expense ratios in Japan (up 280 basis points year-over-year), largely due to digital transformation initiatives; if these investments do not translate into commensurate productivity gains, net margins may remain under pressure.
  •  Aflac's significant exposure to Japan subjects it to persistent currency fluctuations and economic uncertainty-yen depreciation directly impacts reported USD earnings and the efficacy of capital deployment (including 65% of debt held in yen), increasing volatility in both reported revenue and earnings per share.
  •  Variable net investment income was materially below long-term targets in the quarter (down 10.5% in yen terms for Japan), highlighting the ongoing risk from persistent low global bond yields and challenging investment environments, which could lead to lower investment returns and net margins over the long-term.
  •  Persistent sluggishness in U.S. sales (only a 2.7% year-over-year increase), still not at historical growth rates, and dependence on agent recruitment and effectiveness in the traditional distribution channel, points to execution risk; failure to reinvigorate U.S. sales growth may limit future revenue expansion and earnings diversification.

Valuation

How have all the factors above been brought together to estimate a fair value?

  • The analysts have a consensus price target of $117.71 for Aflac based on their expectations of its future earnings growth, profit margins and other risk factors.
  • However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $137.0, and the most bearish reporting a price target of just $98.0.
  • In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $17.5 billion, earnings will come to $3.6 billion, and it would be trading on a PE ratio of 17.7x, assuming you use a discount rate of 7.1%.
  • Given the current share price of $125.6, the analyst price target of $117.71 is 6.7% lower. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
  • We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Aflac?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Read more narratives

Fair Value vs Share Price

US$117.71
vs US$125.66.7% overvalued intrinsic discount
PastFuture023b2015201820212024202620272029Revenue US$17.5bEarnings US$3.6b
-1.1%
Revenue growth
20.5%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Aflac

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Established dividend payer and fair value.

Market capUS$63.3b
PB2.1x
Estimated Growth-0.5%
Dividend Yield1.9%
Full analysis

CEO & management

Daniel Amos
CEO
5.0yrs
CEO Tenure

Through its subsidiaries, provides supplemental health and life insurance products.